These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 17713270)

  • 1. [Pilot study of a cell membrane like biomimetic drug-eluting coronary stent].
    Fan D; Jia Z; Yan X; Liu X; Dong W; Sun F; Ji J; Xu J; Ren K; Chen W; Shen J; Qiu H; Gao R
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Jun; 24(3):599-602. PubMed ID: 17713270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
    van der Giessen WJ; Sorop O; Serruys PW; Peters-Krabbendam I; van Beusekom HM
    JACC Cardiovasc Interv; 2009 Apr; 2(4):284-90. PubMed ID: 19463438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.
    Nakano K; Egashira K; Masuda S; Funakoshi K; Zhao G; Kimura S; Matoba T; Sueishi K; Endo Y; Kawashima Y; Hara K; Tsujimoto H; Tominaga R; Sunagawa K
    JACC Cardiovasc Interv; 2009 Apr; 2(4):277-83. PubMed ID: 19463437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.
    Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE
    JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable phosphorylcholine copolymer for cardiovascular stent coating.
    Liu J; Wang J; Xue YF; Chen TT; Huang DN; Wang YX; Ren KF; Wang YB; Fu GS; Ji J
    J Mater Chem B; 2020 Jun; 8(24):5361-5368. PubMed ID: 32458930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomic layer deposition enhanced grafting of phosphorylcholine on stainless steel for intravascular stents.
    Zhong Q; Yan J; Qian X; Zhang T; Zhang Z; Li A
    Colloids Surf B Biointerfaces; 2014 Sep; 121():238-47. PubMed ID: 25016426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved blood compatibility of rapamycin-eluting stent by incorporating curcumin.
    Pan CJ; Tang JJ; Shao ZY; Wang J; Huang N
    Colloids Surf B Biointerfaces; 2007 Sep; 59(1):105-11. PubMed ID: 17540543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of stent coating on stent deliverability: direct randomised comparison of drug eluting and bare metal stents using the same stent platform.
    Siminiak T; Link R; Wołoszyn M; Kałmucki P; Baszko A
    Kardiol Pol; 2012; 70(10):998-1002. PubMed ID: 23080088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating.
    Wessely R; Hausleiter J; Michaelis C; Jaschke B; Vogeser M; Milz S; Behnisch B; Schratzenstaller T; Renke-Gluszko M; Stöver M; Wintermantel E; Kastrati A; Schömig A
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):748-53. PubMed ID: 15681298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-restenosis study on a new drug eluting stent].
    Zhao A; Zhang H; Huang N; Zhang B; Yang K; Li Z; Zhao H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Aug; 25(4):856-9, 878. PubMed ID: 18788296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model.
    New G; Moses JW; Roubin GS; Leon MB; Colombo A; Iyer SS; Tio FO; Mehran R; Kipshidze N
    Catheter Cardiovasc Interv; 2002 Oct; 57(2):266-71. PubMed ID: 12357534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-eluting stent endothelium: presence or dysfunction.
    van Beusekom HM; Serruys PW
    JACC Cardiovasc Interv; 2010 Jan; 3(1):76-7. PubMed ID: 20129573
    [No Abstract]   [Full Text] [Related]  

  • 17. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis.
    Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C
    Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal course of neointimal formation after drug-eluting stent placement: is our understanding of restenosis changing?
    Finn AV; Nakazawa G; Kolodgie FD; Virmani R
    JACC Cardiovasc Interv; 2009 Apr; 2(4):300-2. PubMed ID: 19463440
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease.
    Airoldi F; Di Mario C; Ribichini F; Presbitero P; Sganzerla P; Ferrero V; Vassanelli C; Briguori C; Carlino M; Montorfano M; Biondi-Zoccai GG; Chieffo A; Ferrari A; Colombo A
    Am J Cardiol; 2005 Sep; 96(5):664-7. PubMed ID: 16125491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.